New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
16:13 EDTTKPYY, ACTActavis confirms patent challenge on generic Colcrys
Actavis (ACT) confirmed that it has filed an Abbreviated New Drug Application with the U.S. FDA seeking approval to market Colchicine Tablets USP, 0.6 mg. Actavis' ANDA product is a generic version of Takeda's (TKPYY) Colcrys, which is a prescription medicine used in adults to prevent and treat gout flares. Takeda Pharmaceuticals U.S.A. filed suit against Actavis on February 27 in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.
News For ACT;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2015
16:55 EDTTKPYYTakeda confirms FDA approval of Ninlaro
Takeda Pharmaceutical Company Limited announced that the FDA has approved Ninlaro capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
10:52 EDTTKPYYFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use